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when stimulated with IL-17 and tumor
necrosis factor-a. Out of 160 genes, 53
‘‘synergistic’’ genes were identified in
at least one of the aforementioned
published studies; our RNA-seq analy-
sis identified 14 additional upregulated
DEGs (Supplementary Table S2 online),
further emphasizing the contribution
of this immunological circuit in the
pathogenesis of psoriasis. One of these
genes was SPRR2B; staining for the
protein product of this gene confirmed
increased expression in psoriatic
lesional skin (Figure 2c), corroborating
differences at the protein level of a
gene identified uniquely by RNA-seq
that is potentially informative with
regard to active molecular pathways
in psoriasis.
The transcriptomic profiling of
psoriasis has led to an increased
understanding of disease pathogenesis.
Although microarray technologies
have been instrumental in this regard,
it is clear that these tools detect an
incomplete set of DEGs. RNA-seq can
be used to supplement these prior
technologies. Here, the use of RNA-
seq methods substantially increased
the number of psoriasis-related DEGs.
Furthermore, DEGs that were uniquely
identified by RNA-seq, but not in
other published microarray studies,
further supported the role of IL-17 and
tumor necrosis factor-a synergy in
psoriasis. Examination of one of these
factors at the protein level confirmed
that RNA-seq is a powerful tool that
can be used to identify molecular
factors present in psoriasis lesions, and
may be useful in the identification
of therapeutic targets that to our knowl-
edge have not been reported pre-
viously. Further studies are in progress
to determine the biological signifi-
cance of DEGs uniquely discovered by
RNA-seq.
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TO THE EDITOR
Bullous pemphigoid (BP) is a sub-
epidermal blistering skin disease char-
acterized by an autoimmune response
to BP180 and BP 230, both of which
are hemidesmosomal proteins in the
basement membrane zone. Pathogenic
mechanisms of BP include complement
activation, recruitment of mast cells,
neutrophils, and eosinophils, liberation
of proteolytic enzymes, and direct
interference with the adhesion function
of BP180 (Kasperkiewicz and Zillikens,
2007; Iwata et al., 2009).
CC chemokine ligand (CCL)24 and
CCL26 are ligands for CC chemokine
receptor (CCR)3, which is expressed on
eosinophils and mast cells (Romagnani
et al., 1999). We have previously repor-
ted that serum levels of CCL26, but
not CCL24, significantly elevate in
patients with atopic dermatitis, and that
serum CCL26 levels are correlated withAbbreviations: BP, bullous pemphigoid; CCL, CC chemokine ligand; CCR, CC chemokine receptor
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eosinophil numbers in peripheral blood
(Kagami et al., 2003). We have also
revealed that fibroblasts from lesional
skin of cutaneous T-cell lymphoma
express higher amounts of CCL26
mRNA (Miyagaki et al., 2010). These
patients often show eosinophilia. How-
ever, the relationship between CCL26
and BP remains unclear.
In this study, we quantified both
blister fluid and serum CCL26 levels
in BP patients. We also examined
the expression of CCL26 in lesional
skin from BP patients by immuno-
histochemistry.
After giving informed consent, 25
patients with BP (13 men and 12
women, mean±SD age: 67.2±20.2
years) and 29 healthy individuals (16
men and 13 women, 53.7±20.3 years)
were enrolled in this study. In addition,
we collected blister fluid from six BP
patients and six burn patients. The
medical ethics committee of the Uni-
versity of Tokyo approved all aspects of
this study according to the Declaration
of Helsinki Principles. The diagnosis of
BP was made based on clinical and
histological features. All sera and blister
fluid were collected and stored at
20 1C, until use.
We used CCL24 and CCL26 immu-
noassay kits (R&D systems, Minneapo-
lis, MN). These levels were measured
according to the manufacturer’s instruc-
tions. Optical densities were measured
at 450 nm with a Bio-Rad Model 550
microplate reader (Bio-Rad Labora-
tories, Hercules, CA). Statistical ana-
lyses were performed using
Mann–Whitney U-test for comparison
between BP and controls. We used the
Wilcoxon signed-ranks test in the com-
parison of serum CCL26 levels before
and after treatment. Correlation coeffi-
cients were determined by using the
Spearman rank correlation test. Po0.05
was considered significant.
Biopsy specimens obtained from
lesional skin of patients with BP and
control subjects were used for immuno-
histochemical staining. We used para-
ffin-embedded tissue sections and
anti-human CCL26 goat polyclonal anti-
body (AF653, R&D systems, 7.5mgml1).
Purified goat IgG (sc-2028, Santa Cruz
Biotechnology, Santa Cruz, CA) was
used as an isotype-matched control.
Fluid CCL26 levels, but not CCL24
levels, in BP patients were significantly
higher than those in burn patients
(1718.5±676.9 vs. 16.1±5.3 pgml1,
Po0.005, and 615.9±691.7 vs. 155.9±
126.6pgml1, respectively; Figure 1a
and b). We also measured serum CCL26
levels in BP patients and compared
them with those of healthy individuals.
BP patients showed higher serum
CCL26 levels, but not CCL24 levels,
than healthy individuals (39.9±22.2
vs. 25.3±6.0pgml1, Po0.0001, and
269.4±305.4 vs. 234.5±128.4pgml1,
respectively; Figure 1c and d). Further-
more, serum CCL26 levels significantly
decreased from 46.0±28.0 to 33.7±
9.6pgml1 after oral corticosteroid treat-
ment (n¼ 11, Po0.05; Figure 1e). In
addition, we assayed serum CCL26 levels
of pemphigus vulgaris and pemphigus
foliaceus patients, but no significant
difference was found (data not shown).
Next, we compared serum CCL26
levels in BP patients with other data
that reflect the disease activity of BP
(Kakinuma et al., 2003). The serum
CCL26 levels were significantly corre-
lated with eosinophil numbers in
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Figure 1. Blister fluid and serum CCL26 levels. Blister fluid CCL26 (a) and CCL24 (b) levels in bullous pemphigoid (BP) and burn patients. Serum CCL26
(c) and CCL24 (d) levels in patients with BP and control subjects. (e) Serum CCL26 levels in patients with BP, before and after oral corticosteroid treatment.
Data are presented as mean±SD. *Po0.05, **Po0.005, and ***Po0.0001. Correlation coefficient between serum CCL26 levels and eosinophil numbers
in peripheral blood (f), or serum CCL17 levels (g) in BP patients.
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peripheral blood (r¼0.59, Po0.05;
Figure 1f) and serum CCL17 levels
(r¼0.45, Po0.05; Figure 1g).
CCL26 was expressed strongly in
lesional and adjacent epidermal kerati-
nocytes of patients with BP and weakly in
vascular endothelial cells of the lesional
skin. In particular, superficial keratino-
cytes showed higher CCL26 levels than
basal keratinocytes (Figure 2a). In normal
skin, CCL26 was expressed weakly in
epidermal keratinocytes but no posi-
tive signal was found in the dermis
(Figure 2b).
Increased expressions of CCR3 li-
gands, such as CCL11 and CCL13, in
lesional skin of BP have been reported
(Gounni Abdelilah et al., 2006). We
have previously demonstrated that
serum levels of CCL28, another ligand
of CCR3, are increased in patients with
BP or atopic dermatitis (Kagami et al.,
2005a). In this context, CCR3 ligands
seem to be important for BP. However,
CCL24 production was not upregulated
in BP patients. Other CCR3 ligands, but
not CCL24, are produced by keratino-
cytes or fibroblasts, which may account
for the difference between CCL24 and
other CCR3 ligands.
Teraki et al. (2001) have shown that
IL-4- and IL-13-producing skin-homing
memory T cells are increased in peri-
pheral blood and blister fluid of BP
patients. In addition, IL-4 and IL-13
induce production of CCL26 by kerati-
nocytes (Kagami et al., 2005b). There-
fore, we speculate a possible role of
CCL26 in BP. BP patients have T cells
that secrete IL-4 and IL-13 (Teraki et al.,
2001). These cytokines stimulate pro-
duction of CCL26 by keratinocytes,
which induces migration of mast cells
into dermis (Romagnani et al., 1999).
Mast cells enhance migration of neu-
trophils and eosinophils, both of which
cleave the extracellular, collagenous
domain of 180-kDa hemidesmosomal
protein of the basement membrane
zone, which finally causes blister for-
mation in BP (Kasperkiewicz and Zilli-
kens, 2007).
In conclusion, we showed that
CCL26, but not CCL24, levels were
significantly increased in BP and de-
creased after treatment, and that
CCL26 was strongly expressed in the
lesional skin from patients with BP.
These results suggest that serum CCL26
levels are useful for assessing the
disease activity of BP, and that CCL26
has some role in the development of
BP. Functional blocking of CCL26 may
be another target for treatment.
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Figure 2. Immunohistochemical staining of CCL26 in BP. CCL26 expression in the lesional skin
of bullous pemphigoid (BP) patients (a) and healthy individuals (b) were examined with
immunohistochemical staining. An arrow indicates endothelial cells. Bar¼ 0.2mm.
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